Vaxart, Inc.

NASDAQ:VXRT

Biotechnology

Healthcare
$0.53 -1.75%

-$0.01 today

Market cap
$129.30M
Beta
1.09
P/E (TTM)
3.6
EPS (TTM)
$0.15
52W Low $0.26High $0.84

Volume 0.12M

Average 0.41M

VXRT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Vaxart, Inc.NASDAQ: VXRT

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 240.65M shares rose 5.6% year over year, behind the +14.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 4.5% from the prior quarter. Over 3 fiscal years it compounded at -22.1% a year.

Context

  • Weighted avg shares increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5.6% toward the trailing-twelve-month pace of +14.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
240.65M+4.5% QoQ
Last fiscal yearDec 2025
230.27M-52.7% YoY
LTMMar 2026
232.05M+14.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.6%——
1 year-52.7%——
3-year CAGR-22.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
230.27M USD
Year-over-year change
-52.7%
4-year CAGR
-17.1%

Weighted Avg Shares vs competitors

How VXRT compares with its peers on the latest reported figures

  • VXRT's LTM Mar 2026 weighted avg shares of 232.05M shares is the 2nd highest of the 10 companies compared; the peer median is 52.9M shares.
  • Its year-over-year change of +14.5% is the 7th highest of 10, against a peer median of +82.9%.
  • Over three fiscal years its annual growth of -22.1% compares with a peer median of +44.1%.
VXRT Competitors Peer median
Weighted Avg Shares for VXRT and competitors
Company Period LTM YoY 3-year CAGR
CBUSCibus, Inc.LTM Mar 2026301.04M +1164.8%-7.5%
VXRTVaxart, Inc.LTM Mar 2026232.05M +14.5%-22.1%
TCRXTScan Therapeutics, Inc.LTM Mar 2026129.84M +7.6%+75.4%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026107.08M +1278.7%+372.5%
RLMDRelmada Therapeutics, Inc.LTM Mar 202655.31M +82.9%+10.0%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 202652.9M +2.4%+4.8%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
CAMPCAMP4 Therapeutics CorporationLTM Mar 202637.54M +102.0%—
FBIOFortress Biotech, Inc.LTM Mar 202628.39M +34.1%+67.6%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
Peer median (excluding VXRT) 52.9M+82.9%+44.1%

Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue892K107K7.38M28.7M237.26M
Cost of Revenue48.75M04.5M00
Gross Profit(47.86M)107K2.88M28.7M237.26M
Gross Margin-5365.1%100.0%39.0%100.0%100.0%
Research & Development48.75M81.05M68.14M74.21M201.58M
Selling, General & Admin21.89M29.39M22.58M20.78M17.61M
Operating Expenses24.9M114.69M86.23M94.99M219.18M
Depreciation & Amortization2.43M5.81M8.62M8.85M8.58M
EBITDA(66.45M)(100.58M)(72.13M)(54.87M)28.21M
EBITDA Margin-7449.7%-94000.9%-977.5%-191.2%11.9%
Operating Income(72.75M)(114.59M)(83.35M)(66.29M)18.07M
Operating Margin-8156.1%-107090.7%-1129.5%-231.0%7.6%
Interest Income81K1.25M2.65M2.54M1.6M
Interest Expense1.48M1.31M1.45M2.97M2.82M
Other Income / Expenses2.39M6.9M1.14M(395K)(1.27M)
Income Before Tax(70.36M)(107.69M)(82.2M)(66.69M)16.8M
Pre-Tax Margin-7888.2%-100645.8%-1114.0%-232.4%7.1%
Income Tax Expense107K67K261K260K476K
Net Income(70.47M)(107.76M)(82.47M)(66.95M)16.33M
Net Margin-7900.2%-100708.4%-1117.6%-233.3%6.9%
EPS (Basic)(0.14)(0.22)(0.17)(0.14)0.07
EPS (Diluted)(0.14)(0.22)(0.17)(0.14)0.07
Weighted Avg Shares487.26M487.26M487.26M487.26M230.27M
Weighted Avg Shares (Diluted)487.26M487.26M487.26M487.26M230.35M

Vaxart, Inc.

NASDAQ:VXRT

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.